Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24952968 | 0.89 | GCK (0.39) | GCK | |
| SCHEMBL24954122 | 0.88 | GCK (0.38) | GCKCYP3A4CYP1A2CYP2C9SLC6A3 | |
| SCHEMBL24953827 | 0.88 | GCK (0.45) | GCK | |
| SCHEMBL24953721 | 0.87 | TLR8 (0.36) | GCK | |
| SCHEMBL24952909 | 0.87 | GCK (0.42) | GCK | |
| SCHEMBL24952903 | 0.87 | GCK (0.42) | GCK | |
| SCHEMBL24954557 | 0.86 | CYP3A4 (0.35) | GCKCYP3A4CYP1A2CYP2C9SLC6A3 | |
| SCHEMBL24953806 | 0.83 | CCNE1 (0.45) | GCK | |
| SCHEMBL24953760 | 0.83 | CCNE1 (0.45) | GCK | |
| SCHEMBL24952912 | 0.83 | GCK (0.39) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | GCK 1519/4885CYP3A4 2496/4885CYP1A2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.